DAWN - Company ID 0001845337
The table below shows Day One Biopharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $158.18M | $131.16M | $0.00 | $0.00 | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $148.13M | $227.70M | $130.52M | $85.62M | $43.58M | $9.10M |
| SG&A |
Day One Biopharmaceuticals, Inc. reported annual revenue of $158.18M for fiscal year 2025. That is up 20.6% from $131.16M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $120.59M |
| $115.45M |
| $75.54M |
| $61.29M |
| $29.16M |
| $4.68M |
| Operating income | -$127.75M | -$217.27M | -$206.06M | -$146.91M | -$72.74M | -$13.78M |
| Income tax | -$1.98M | $7.14M | $0.00 | $0.00 | - | - |
| Net income | -$107.32B | -$95.50B | -$188.92B | -$142.18B | -$72.75B | -$40.51M |
| EPS (diluted) | -$1.04 | -$1.02 | -$2.37 | -$2.17 | -$4.62 | -$7.33 |